Fibrogen presents data from phase 3 matterhorn trial of roxadustat in patients with anemia of lower risk transfusion-dependent myelodysplastic syndromes at american society of hematology annual meeting

A post hoc analysis of patients with higher transfusion burden at baseline showed a larger percentage of patients achieved transfusion independence ≥ 56 days with roxadustat vs. placebo (36.1% vs 11.5%; p=0.047 ǂ ).
FGEN Ratings Summary
FGEN Quant Ranking